Physician organization urges lawmakers to prioritize access to safe, approved medications
WASHINGTON (June 7, 2017) – The Alliance for Patient Access (AfPA) made the following statement about the amendment to the FDA Reauthorization Act of 2017 (H.R. 2430) which updates the Prescription Drug User Fee Act (PDUFA) before the House Energy and Commerce Committee regarding the importation of prescription drugs from other countries.
STATEMENT FROM BRIAN KENNEDY, EXECUTIVE DIRECTOR, ALLIANCE FOR PATIENT ACCESS:
“The amendment, that would allow the importation of drugs from other countries, jeopardizes patients’ ability to access safe, FDA approved medicines. When drugs enter our country without going through FDA approval the drug supply is adulterated and physicians may lose confidence in the medications they prescribe to patients.
“Because of the extensive FDA approval process, the U.S. drug market is one of the safest in the world. Drugs imported from foreign countries aren’t subject to FDA regulation, including meeting the standards for safety and efficacy, so health care providers would have to consider the possibility of counterfeit medications and drugs of substandard quality.
“We urge the House Energy and Commerce Committee to reject this amendment because patient safety and access must be a top priority.”
The Alliance for Patient Access is a national network of physicians dedicated to ensuring patient access to approved therapies and appropriate clinical care.